Ascendis Pharma A/S vs Upstart Holdings Inc — how do they compare? Ascendis Pharma A/S trades at $254.5 (market cap $16.67B), while Upstart Holdings Inc trades at $29.93 (market cap $2.91B). The key difference: Ascendis Pharma A/S is far larger — about 5.7× Upstart Holdings Inc's market cap, and Ascendis Pharma A/S is trading nearer its 52-week high, Upstart Holdings Inc nearer its low. Which is the better fit depends on your goals.
| ASND | UPST | |
|---|---|---|
Market Cap | $16.67B | $2.91B |
Sector | Health | Financials |
52-Week High | $277.18 | $73.76 |
52-Week Low | $189.74 | $24.22 |
Enterprise Value | $17.04B | — |
Trailing returns across standard periods
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →Upstart Holdings Inc provides credit services. The company provides a proprietary, cloud-based, artificial intelligence lending platform. The platform aggregates consumer demand for loans and connects it to the network of Upstart AI-enabled bank partners. The revenue of the company is primarily comprised of fees paid by banks.
Read more on UPST →